A five-year survival rate is a hollow victory if it leaves the patient in a state of biological bankruptcy. In many ways, we’re curing the tumor by liquidating the host’s long-term assets. When we look at why cancer survivors age a decade over a single treatment cycle, two main theories are currently competing for the floor.

The first is the Senescence Seed. This is the standard narrative where chemotherapy and radiation act as scorched-earth tactics, generating a sudden, massive population of senescent cells. These cells leak SASP (Senescence-Associated Secretory Phenotype), which functions like a systemic poison. It’s essentially a volume problem: we’re seeding the body with more "zombie cells" than the innate immune system can clear, leading to organ failure years down the line.

The second theory, and the one I find more compelling, is Signaling Exhaustion. I suspect it’s not just the presence of damaged cells, but a permanent re-calibration of the GSK-3β/AMPK axis. The extreme metabolic stress of oncology protocols forces the entire system into a "survival flux" it can’t escape. We're doing more than creating noise; we’re breaking the cell’s semantic scaffold. By over-triggering these pathways to stop a tumor, we permanently destabilize membrane integrity and protein folding. The cell "forgets" its youthful homeostatic set-point because the signaling environment is stuck in a post-traumatic state.

I’m betting on Signaling Exhaustion. If this were purely a cell-count issue, senolytics would already be a panacea for survivors. They aren’t. Survivors of pediatric cancers often hit geriatric milestones in their 30s because their metabolic clock has been overclocked until it breaks.

We have to move past survival as the only metric that matters. We need trials that pair traditional oncology with GSK-3β modulators and membrane stabilizers—not just to kill the cancer, but to protect the survivor’s longevity flux. Unless we bridge the gap between oncology and longevity labs, we aren’t saving lives; we’re just delaying a systemic collapse. I’m looking for collaborators to help map these signaling drifts and track the long-term proteostatic debt these patients carry.